Alfonso Tafur: Different Cancer Sites Drive Different Thrombotic Phenotypes
Alfonso Tafur, Vascular Medicine Fellowship Program Director at University of Chicago, Director of Vascular Medicine Department at NorthShore University, shared on LinkedIn:
”For years, many of us have treated cancer-associated thrombosis as if it were a single disease.
The data keep reminding us: it isn’t.
In the RIETE Registry, we looked at 18,000+ cancer patients vs. 88,000 without.
Within 90 days — 2.5× higher recurrent VTE, ~40% higher major bleeding.
But the real signal? Cancer site matters.
Lung and pancreatic drive clot risk. GI and GU drive bleeding risk.
Cancer-associated thrombosis is not one disease.
It is many biologically different thrombotic phenotypes.
Proud to be part of this team working toward precision vascular care.”
Proceed to the video attached to the post.
Stay updated with Hemostasis Today.
-
Sep 23, 2026, 12:34Hiteshi K.C. Chauhan: Why Mechanical Valve Thrombosis Is a Systems Failure, Not Just an Anticoagulation Error
-
Sep 23, 2026, 12:33World Thrombosis Day 2026 Puts Women’s Health in Focus – JTH
-
Sep 23, 2026, 12:30Zain Khalpey: How a Sudden Blockage Causes Myocardial Infarction
-
Sep 23, 2026, 12:16Apurva Popat: When Heparin Triggers Thrombosis
-
Sep 23, 2026, 12:14Zahra Ghasemi: The Power of Voluntary Blood Donation
-
Sep 23, 2026, 12:04Leo Nicolai: Activated Platelets Get Trapped in the Spleen During Thrombosis
-
Sep 23, 2026, 12:01Francisco Chacón-Lozsán: Rethinking PE Risk in 2026
-
Sep 23, 2026, 11:58Ifeanyichukwu Ifechidere: Factor V Leiden Requires Context Beyond the Genetic Result
-
Sep 23, 2026, 11:35Martina Wolff: How Platelet Membrane Protrusions Shape Hemostasis and Thrombosis